A Study of AZD0292 in Chinese Participants With Bronchiectasis and Chronic Pseudomonas Aeruginosa Colonization
← catalyst calendarNCT07774403 · readout in 517 d
Sponsored by AstraZeneca (industry) · AZN — their whole pipeline →.
Phase
Phase 2
Status
Recruiting
Study type
Interventional
Design
Randomized · Triple · Prevention
Enrollment
84estimated
Sites
40
Country
China
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2026-06-24 | actual | When the study began enrolling |
| Primary completion | 2028-01-18 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2028-06-06 | estimated | The whole study's end, after follow-up |
| First posted | 2026-08-19 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-08-19 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Bronchiectasis With Pseudomonas Aeruginosa Colonization
Interventions
- Drug: AZD0292
- Other: Placebo
Primary outcome
what the primary-completion date above is the date OFAnnualized rate of exacerbations over a variable follow-up time
measured Min 28 weeks, max 52 weeks
Permalink · AZN's whole pipeline · Catalyst calendar · Every registered study · What changed